cholecystolithiasis
Conditions
Interventions
trial group:Before the end of the surgery, after the gallbladder is removed, the incision site is infiltrated with 20ml of 0.33% ropivacaine combined with 2mg of butorphanol mixture, including 10ml of
control group:Before the end of the surgery, after the gallbladder is removed, 20ml of 0.33% ropivacaine is used for incision infiltration at the surgical incision site, with 10ml of periumbilical inc
Sponsors
Qionglai Medical Center Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1) Age range from 18 to 60 years old, regardless of gender; 2) Voluntarily accept the experiment and sign the consent form for surgery and anesthesia; 3) ASA grade I-II, planned for daytime laparoscopic cholecystectomy surgery;
Exclusion criteria
Exclusion criteria: 1) Patients with central nervous system diseases or respiratory dysfunction; 2) Uncontrolled hypertension; Heart disease (i.e. those with a heart function of level III or above); Significant abnormalities in liver and kidney function (i.e. indicators higher than twice the normal value). 3) People who are highly sensitive to butorphanol tartrate and chlorpheniramine; 4) Drug or alcohol abusers; 5) Participated in other clinical trials within 4 weeks prior to the start of the study; 6) Individuals who are currently taking or have taken MAO inhibitors (such as Eugenin, Phenylhydrazine, etc.) within 2 weeks prior to the start of this experiment; 7) During surgery, there may be significant bleeding or prolonged surgery time, or the surgery may be terminated due to other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| visual analogue scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Ramsay Sedation score;Nausea and vomiting score; | — |
Countries
China
Contacts
Public ContactLiu Ting
Qionglai Medical Center Hospital
Outcome results
None listed